- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
Purpose Bitcoin ETF
Soma Gold Corp.
Black Swan Graphene
CI Galaxy Bitcoin ETF
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
DNA Nanobots to Target Cancer Cells in First Human Trial
3Tags reported that Professor Ido Bachelet of Israel’s Bar-Ilan University confirmed that nanobots capable of fighting cancerous cells no longer a thing of science fiction.
3Tags reported that Professor Ido Bachelet of Israel’s Bar-Ilan University confirmed that nanobots capable of fighting cancerous cells no longer a thing of science fiction. Indeed, the first DNA nanobot trial in a human subject will take place in 2016.
According to the report:
Nanobots can also have multiple “payloads” in them, and can be programmed so that they know which drug to expose to specific molecules. This means that nanobots work well in combination therapy—where multiple drugs are used at once—and can be timed so that the different drugs don’t interfere with one another. As of December 2014, the nanobots that Bachelet’s team have developed can recognize 12 different types of cancerous cells.
3Tags also notes that:
In that case, when can we expect this miracle treatment to hit the public? The first DNA nanobot trial in a human subject will take place this year—in fact, it could be happening right now—on a person with late-stage leukemia. The patient is expected to die, but Bechelet believes that, based on previous animal trials, the nanobots can remove the cancer in the span of a month. If the trial goes well, we could see nanotechnology hit the public in one-to-five years.”
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.